Aimmune Therape…
ProfileJobs

Aimmune Therapeutics

Suggest Edit
    • Healthbiotechdrug developmentpharma

    We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. The Company's therapeutic approach, which it refers to as Characterized Oral Desensitization ImmunoTherapy, or CODITTM, is designed to desensitize patients to food allergens and thereby reduce the risk of having an allergic reaction upon accidental exposure, or reduce symptom severity should an allergic reaction occur. CODIT is intended to reduce meaningfully the burden and anxiety experienced by food-allergic patients and their families.

    Market capitalization(2018-04-23)
    $1.6 B
    Type
    Public
    HQ
    Brisbane, US
    Founded
    2011
    Size (employees)
    122 (est)+20%
    Website
    aimmune.com
    Aimmune Therapeutics was founded in 2011 and is headquartered in Brisbane, US
    Report incorrect company information

    Aimmune Therapeutics Office Locations

    Aimmune Therapeutics has offices in Greater London and Brisbane
    Brisbane, US (HQ)
    200 8000 Marina Blvd
    Greater London, GB
    344-354 Grays Inn Rd
    Show all (2)
    Report incorrect company information

    Aimmune Therapeutics Financials and Metrics

    Aimmune Therapeutics Financials

    USD

    Net income (Q2, 2017)

    		(32.5 m)

    EBIT (Q2, 2017)

    		(33 m)

    Market capitalization (23-Apr-2018)

    		1.6 b

    Cash (30-Jun-2017)

    		84.5 m
    Aimmune Therapeutics's current market capitalization is $1.6 b.
    Annual
    USDFY, 2015FY, 2016

    General and administrative expense

    		16.2 m26.9 b

    R&D expense

    		19.8 m54.6 b

    Operating expense total

    		36 m81.5 b

    EBIT

    		(36 m)(81.5 b)
    Quarterly
    USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

    General and administrative expense

    		5.2 m5.7 m6.5 m6.4 m8.9 m10.8 m

    R&D expense

    		3.9 m10 m11.8 m15.9 m17.4 m22.2 m

    Operating expense total

    		9 m15.7 m18.3 m22.2 m26.3 m33 m

    EBIT

    		(9 m)(15.7 m)(18.3 m)(22.2 m)(26.3 m)(33 m)
    show all
    Annual
    USDFY, 2015FY, 2016

    Cash

    		76.7 m124 m

    Inventories

    		5.6 m2.7 m

    Current Assets

    		197.5 m251.7 m

    PP&E

    		2.7 m10.4 m
    Quarterly
    USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

    Cash

    		58.5 m112.7 m65 m74.4 m76.9 m78.7 m84.5 m

    Current Assets

    		60.6 m217.8 m185.2 m172.8 m152.6 m248.9 m242.6 m

    PP&E

    		1.3 m1.8 m3.7 m7 m9 m11.1 m13.1 m

    Total Assets

    		62.1 m222.8 m199.9 m185.7 m173.7 m276.3 m256.4 m
    show all
    Annual
    USDFY, 2015FY, 2016

    Net Income

    		(35.8 m)(80.8 m)

    Depreciation and Amortization

    		115 k534 k

    Inventories

    		4 m

    Accounts Payable

    		1.1 m(994 k)
    Quarterly
    USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

    Net Income

    		(9 m)(15.5 m)(18.1 m)(22.1 m)(25.9 m)

    Accounts Payable

    		309 k1 m1.8 m1.3 m1.5 m1.7 m
    show all
    USDY, 2017

    Financial Leverage

    		1.1 x
    Show all financial metrics

    Aimmune Therapeutics Operating Metrics

    FY, 2016

    Patents Issued

    		2
    Show all operating metrics
    Report incorrect company information

    Competitors

    Celldex Therapeutics
    Health - Public
    Cesca Therapeutics
    Health - Public
    MannKind Corporation
    Health - Public
    Innoviva
    Health - Public
    Compare competitors
    Download PDF